

Remarks

The Communication mailed March 30, 2006 has been received and reviewed. Claims 1-17 are pending in the application and subject to restriction. Applicants elect, without traverse, to prosecute the claims of Group II, *i.e.*, claims 1-9, where SEQ ID NO:9 is used.

Claim 18 is new. Support for claim 18 can be found throughout the specification, for example in paragraph [00104], Example 8: NF- κ B dependent reporter gene assay. No new matter has been added. Applicants believe newly added claim 18 falls in the elected invention group.

If questions should remain after consideration of the foregoing, the Examiner is kindly requested to contact applicants' agent at the address or telephone number given herein.

Respectfully submitted,

/S/

Li Feng, Ph.D.
Registration No. 57,292
Agent for Applicants
TRASKBRITT, PC
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: April 27, 2006

LF/lf

Document in ProLaw